Who is sponsoring NCT04827745?

NCT04827745 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT04827745?

Interventions in NCT04827745: BLINCYTO (Blinatumomab).

What condition does NCT04827745 study?

NCT04827745 studies Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD).

Is NCT04827745 still recruiting?

NCT04827745 is currently completed. Last updated 3 July 2025.

Last reviewed 2025-07-03 · How we verify

NCT04827745

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

Completed Phase 2 Last updated 3 July 2025

What this trial tests

Phase 2 trial testing BLINCYTO (Blinatumomab) in Mixed Phenotype Acute Leukemia (MPAL) in 2 participants. Completed in 22 May 2025.

Timeline

11 June 2021

Primary endpoint
22 May 2025

22 May 2025

Quick facts

Lead sponsor	University of Maryland, Baltimore
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	11 June 2021
Primary completion	22 May 2025
Estimated completion	22 May 2025
Sites	1 location across United States

Drugs / interventions tested

BLINCYTO (Blinatumomab) — full drug profile →

Conditions studied

Mixed Phenotype Acute Leukemia (MPAL) — all drugs for Mixed Phenotype Acute Leukemia (MPAL) →
Measurable Residual Disease (MRD) — all drugs for Measurable Residual Disease (MRD) →

Sponsor

University of Maryland, Baltimore

Who can join

18 and older, any sex, with Mixed Phenotype Acute Leukemia (MPAL) or Measurable Residual Disease (MRD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a research study to find out if a drug called blinatumomab is effective for treating patients with relapsed or refractory (R/R) or measurable residual disease (MRD) CD19-positive mixed phenotypic acute leukemia (MPAL). Measurable Residual Disease (MRD) means that there are a small number of cancer cells remaining after treatment

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle.
Starzer AM, Preusser M, Berghoff AS. · · 2022 · cited 39× · PMID 35510032 · DOI 10.1177/17588359221096219
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6
Effective treatment of relapsed/refractory CD19-positive B/T-type mixed-phenotype acute leukemia with blinatumomab: A case report.
Aoki M, Ishikawa M, Sato T, Taji Y, et al · · 2024 · cited 2× · PMID 39157609 · DOI 10.1002/jha2.933
Mixed phenotype acute leukemia, the dissection of an enigmatic disease in the era of novel therapies.
Karasek M, Kubiszewska I, Sobas M. · · 2025 · cited 1× · PMID 41477275 · DOI 10.3389/fped.2025.1715087

Verify or expand the search:

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04827745 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 3 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04827745.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing